Axol Bioscience Ltd.

Axol Bioscience Ltd. The Best Human Cell Culture Systems for Research Success Contact Axol Bioscience today! www.axolbio.com

Axol offer ready-made, well-characterized stem and functional cells complete with easy-to-understand protocols and video guides for handling them. We are devoted to making high quality, data-rich cellular products that are affordable for all research labs including starting up labs! We believe that all research labs should have easy access to the cells generated using the reprogramming and downstream differentiation technologies.

Single-cell RNA-seq reveals early, motor neuron-specific mitochondrial dysfunction in ALS, shared across FUS and TARDBP ...
20/05/2026

Single-cell RNA-seq reveals early, motor neuron-specific mitochondrial dysfunction in ALS, shared across FUS and TARDBP mutations.

Key findings from Schweingruber, Hedlund et al.

• Transcriptional dysregulation was far stronger in iPSC-derived motor neurons than interneurons
• A core set of mitochondrial gene changes was shared across FUS P525L, FUS R495X, FUS R495X, and TARDBP M337V and extended to C9orf72-ALS patient neurons
• Mitochondrial motility was impaired in ALS motor axons even when mutant FUS stayed nuclear, pointing to an early toxic gain-of-function mechanism independent of protein mislocalization

Read the full document: https://hubs.la/Q04hgxJl0

Together, the data frame mitochondrial dysfunction as a convergent, early driver of motor neuron vulnerability, and a compelling therapeutic target.

Our human iPSC patient-derived motor neurons and ALS disease models support exactly this kind of research.

Learn more: https://hubs.la/Q04hgz5l0 or reach us at [email protected]

We’re pleased to have been welcomed to the cohort of the British Chambers of Commerce Trade Accelerator programme.Develo...
19/05/2026

We’re pleased to have been welcomed to the cohort of the British Chambers of Commerce Trade Accelerator programme.

Developed to address the gap between ambition and ex*****on in UK exports, the programme is a practical, outcomes-driven initiative focused on converting innovation into real international commercial success. It brings together UK industry, government, and in-market partners to support life sciences companies entering high-growth markets such as Singapore and Southeast Asia.

For us, this represents an important opportunity to extend British innovation globally and build meaningful commercial and research partnerships.

What this means in practice

• A structured, six-month programme designed to support entry into high-value international markets
• A practical 10-stage pathway guiding companies from early market exploration to commercial traction and signed deals
• Access to in-market expertise, partner networks, and commercial support to enable confident market entry
• Integrated support across regulatory navigation, market validation, and partnership development
• A coordinated “Team UK” approach, aligning Chambers, government, and financial partners

At Axol Bioscience, we develop human iPSC-derived cell models and tools to enable disease modeling, drug discovery, and translational research across multiple therapeutic areas. Participation in the Trade Accelerator supports our ambition to scale these capabilities internationally and contribute to the global life sciences ecosystem from a strong UK foundation.

Learn more: https://hubs.la/Q04h43Mb0

Our Chief Business Officer, Catherine Elton, and Scientific Group Leader Jamie Bhagwan will be attending this week’s programme event, and we look forward to engaging with fellow cohort members and partners.

With over 475 therapies in development, and 157 active or enrolling trials, and more than 350 companies actively working...
14/05/2026

With over 475 therapies in development, and 157 active or enrolling trials, and more than 350 companies actively working in ALS, and a global ALS market projected to grow from USD 667.3M in 2023 to USD 987.6M by 2030, confidence is returning. Learnings, fuelled by stronger mechanistic hypotheses, and more resilient translational strategies, spanning TDP-43 loss and gain of function biology, cryptic exon regulation, neuroinflammatory pathways, and human-relevant iPSC and 3D models, the ALS community is leveraging these lessons to build smarter, more predictive programs.

Our Scientific Account Manager, Gizem Inak, Project Manager Jessica Tilman and Scientist Hannah Sharplin will be at our booth, ready to discuss how physiologically relevant iPSC-derived models can help bridge the translational gap in ALS drug development.

With over 475 therapies in development, and 157 active or enrolling trials, and more than 350 companies actively working in ALS, and a global ALS market projected to grow from USD 667.3M in 2023 to USD 987.6M by 2030, confidence is returning. Learnings, fuelled by stronger mechanistic hypotheses, and more resilient translational strategies, spanning TDP-43 loss and gain of function biology, cryptic exon regulation, neuroinflammatory pathways, and human relevant iPSC and 3D models, the ALS community is leveraging these lessons to build smarter, more predictive programs.

At Axol, we support ALS drug discovery across the full preclinical workflow, from patient-derived iPSC line generation and banking to disease-relevant differentiation and advanced in vitro models. We provide iPSC-derived motor neurons, astrocytes and microglia, alongside co-culture systems and assay platforms to study key disease mechanisms, assess compound efficacy, and de-risk candidate selection.

Jess will be presenting our new poster titled "Modeling ALS with iPSC-derived motor neurons, microglia and astrocytes".

Stop by to learn how our iPSC-derived models and specialist services can support your ALS research.

Download our brochure: https://hubs.la/Q04gpGy70

Contact us at [email protected]

Neurons are among the most energy-demanding cells in the body, making them vulnerable to mitochondrial dysfunction. This...
13/05/2026

Neurons are among the most energy-demanding cells in the body, making them vulnerable to mitochondrial dysfunction. This vulnerability sits at the core of rare disorders like Leigh syndrome and common neurodegenerative diseases such as Alzheimer's and Huntington's. As mitochondrial-targeted therapies gain traction, human-relevant models for discovery and validation are becoming essential.

Two recent studies from Prigione and colleagues show what this pipeline can look like.

Study 1 – iPSC-based screening in LS neural cells

Cell Stem Cell link: https://hubs.la/Q04gpp1x0
• Sildenafil rescued mitochondrial membrane potential in LS brain organoids
• Neurodevelopmental pathways and calcium responses were restored
• Lifespan was extended in mammalian LS models
• Off-label treatment in six LS patients improved motor function and resilience to metabolic crises

Study 2 – AI augmented organoid screening

Nature link: https://hubs.la/Q04gpj180
• LS organoids with SURF1 variants were paired with a deep learning-driven in silico screen
• Azole compounds (talarozole, sertaconazole) were identified and independently validated in yeast
• Rescue of neuronal morphogenesis in LS neurons and improved organoid growth and lactate profiles
• Effects linked to retinoic acid and lipid metabolism pathways

Platforms built for rare mitochondrial diseases are directly transferable to neurodegeneration research, where mitochondrial health is equally central to disease progression and therapeutic targeting.

At Axol Bioscience, we support this workflow with human iPSC-derived neuronal models for mitochondrial disease and neurodegeneration research: https://hubs.la/Q04gpdRZ0

Contact us at [email protected]

May is ALS Awareness MonthALS is a devastating neurodegenerative disease that continues to challenge patients, families,...
08/05/2026

May is ALS Awareness Month

ALS is a devastating neurodegenerative disease that continues to challenge patients, families, and researchers alike. While awareness is essential, sustained progress depends on giving scientists the right tools to better understand the disease and develop more effective treatments.

At Axol Bioscience, we’re proud to support the ALS research community with physiologically relevant models designed to help researchers study disease mechanisms and generate data that better reflects patient biology. Our work in the ALS space is driven by one goal: to enable stronger, more translational neuroscience research that can ultimately make a difference for people living with ALS.

This month, we also encourage supporting organisations driving patient care, advocacy, and research funding. To learn more about ALS and find ways to support this work, visit: https://hubs.la/Q04fXt7R0

We'll be at the MPS World Summit 2026, 26-29 May in Washington, DCOur Strategic Partnerships Manager, Stuart Prime, Scie...
08/05/2026

We'll be at the MPS World Summit 2026, 26-29 May in Washington, DC

Our Strategic Partnerships Manager, Stuart Prime, Scientific Account Manager Yanis Kasioulis, R&D Ophthalmology Scientist Kevin Gillois, and CEO Liam Taylor will be at booth #131 and looking forward to connecting with new and existing partners working with NAMs, organoids, and microfluidic platforms.

From complex co‑cultures and organoids to sophisticated microfluidic devices, advanced in vitro models are reshaping drug discovery. But MPS platforms and NAMs are only as powerful as the cells within them. Human iPSC‑derived axoCells™ are engineered to integrate seamlessly into MPS workflows, delivering the consistency, functionality, and scalability required for robust, reproducible microphysiological systems.

Kevin will be presenting our new poster "Development of a human iPSC-derived retinal microphysiological co-culture system for dry age-related macular degeneration" on Wednesday, 27 May at 3:15-4:45 PM, poster number 237, abstract number 189.

Learn more about our ophthalmology offerings: https://hubs.la/Q04fXCnV0

Contact us at [email protected].

Modeling Stargardt disease using retinal organoidsIn this study, Watson et al. investigated genotype–phenotype correlati...
06/05/2026

Modeling Stargardt disease using retinal organoids

In this study, Watson et al. investigated genotype–phenotype correlations in Stargardt disease (STGD1) using induced pluripotent stem cell–derived retinal organoids from patients with different ABCA4 genotypes. Retinal organoids from monoallelic late‑onset cases and a biallelic severe case developed all major retinal cell types and expressed ABCA4, validating the model. A consistent disease‑specific phenotype was identified: mislocalisation and retention of photoreceptors within the organoid interior, most prominently affecting cone photoreceptors, with severity correlating to genotype.

Single‑cell RNA sequencing revealed dysregulation of stress‑response, mitochondrial, and phototransduction pathways, suggesting that cellular stress underlies the observed defects. In addition, whole‑genome sequencing and long‑read RNA sequencing resolved previously missing alleles, identifying hypomorphic and homozygous variants and recapitulating retina‑specific splicing defects.

Overall, the study demonstrates that retinal organoids faithfully model STGD1, capture genotype‑dependent disease mechanisms, and provide a powerful platform for genetic resolution, mechanistic studies, and therapeutic development.

Read the full paper: https://hubs.la/Q04fFfFT0

Axol Bioscience offers live human retinal organoids at defined stages of maturation, enabling studies to be performed at developmentally appropriate stages. Want to know more? Contact us at [email protected]

Cell-type-focused compound screen in human organoids reveals CK1 inhibition protects cone photoreceptors from deathA ver...
29/04/2026

Cell-type-focused compound screen in human organoids reveals CK1 inhibition protects cone photoreceptors from death

A very insightful paper by Spirig et al., where human retinal organoids with GFP‑labeled cones were used to screen 2,707 annotated compounds, aiming to identify pathways that either exacerbate or prevent cone photoreceptor death. The authors induced degeneration using glucose starvation, and uncovered broad HDAC I/II inhibition consistently caused severe cone toxicity, while HSP90 inhibition provided short‑term protection but became harmful over longer exposure. Very interestingly, two kinase inhibitors, renamed CS‑KI‑1 and CS‑KI‑2, emerged as robust cone‑preserving hits.

Mechanistic profiling revealed that CS‑KI‑1 acts through CK1 (CSNK1G1) and CS‑KI‑2 through MAPK11, and direct inhibition or cone‑specific shRNA knockdown of CK1 family members significantly improved cone survival. These compounds also protected photoreceptors under oxidative stress and preserved retinal structure in rd10 mice, positioning CK1 inhibition as a promising neuroprotective strategy for diseases such as retinitis pigmentosa and macular degeneration.

Read the full paper: https://hubs.la/Q04dS9PB0

At Axol Bioscience, we generate and ship live retinal organoids, enabling researchers to conduct in vitro studies in human-relevant, physiological models.

Want to learn more? Contact [email protected] for more information.

New whitepaper: Physiologically relevant iPSC-derived retinal models for ophthalmology research & drug discoveryRetinal ...
24/04/2026

New whitepaper: Physiologically relevant iPSC-derived retinal models for ophthalmology research & drug discovery

Retinal diseases are a diverse group of degenerative and genetically driven conditions that progressively impair visual function. While recent advances have improved outcomes in some indications, most retinal disorders, including dry age‑related macular degeneration and inherited retinal diseases, still lack effective disease‑modifying treatments, reinforcing the need for physiologically relevant human model systems.

Our new whitepaper describes how human iPSC‑derived retinal models enable mechanistic studies, toxicity assessment, and improved translational relevance in ophthalmology research.

In this whitepaper, we discuss:

• Key challenges in retinal disease modeling and the limitations of traditional in vivo and in vitro systems

• Phenotypic and functional characterisation of human iPSC‑derived retinal pigment epithelium and microglia relevant to retinal degeneration and inflammation

• The use of iPSC‑derived retinal organoids to recapitulate retinal development, cellular composition, and layered architecture

• Application of physiologically relevant RPE‑based in vitro models to study dry AMD‑associated stressors, including oxidative stress, complement activation, and inflammatory signalling

• Emerging directions toward multi‑lineage and higher‑order retinal model systems to better capture human‑specific disease mechanisms

As ophthalmology moves toward gene‑targeted, cell‑based, and pathway‑specific therapies, well‑characterised iPSC‑derived retinal models are becoming central to translational research and drug discovery.

Download the whitepaper: https://hubs.la/Q04dl0ls0

Our Head of Ophthalmology, Florian Regent, and Scientific Account Manager, Yanis Kasioulis, will be at ARVO next week and look forward to connecting with the vision research community. Speak with the team to learn more about our iPSC‑derived retinal models and specialist services supporting ophthalmic research and drug development.

We'll be at ARVO 2026 Annual Meeting, 3-7 May, in Denver, ColoradoOur Head of Ophthalmology, Florian Regent, and Scienti...
22/04/2026

We'll be at ARVO 2026 Annual Meeting, 3-7 May, in Denver, Colorado

Our Head of Ophthalmology, Florian Regent, and Scientific Account Manager, Yanis Kasioulis, will be on site and looking forward to connecting with leaders from across the ophthalmology and vision research community.

ARVO’s Annual Meeting is the world’s leading educational and networking forum for professionals, trainees, and students working in vision research and eye science, bringing together cutting‑edge science and translational insights.

Florian will be presenting our new poster, titled "Developing an in vitro dry AMD model incorporating multiple retinal cell types derived from human iPSCs" on 3 May, 1:00-2:45 PM, poster number 795 - 0788.

Come and speak with our team to learn more about our human iPSC‑derived retinal cell models and organoids, as well as our specialist services designed to support and accelerate ophthalmic research and drug development programs.

Learn more about our ophthalmology offerings: https://hubs.la/Q04cJksr0

If you’re not attending ARVO but would like to discuss how we can support your projects, please contact us at [email protected].

We'll be at The Target ALS Annual Meeting, 5-7 May, in BostonOur Scientific Group Leader, David Wallbank, is proud to be...
20/04/2026

We'll be at The Target ALS Annual Meeting, 5-7 May, in Boston

Our Scientific Group Leader, David Wallbank, is proud to be representing Axol Bioscience at the Target ALS Annual Meeting from 5-7 May in Boston, USA. The meeting is a great opportunity for members of the innovation ecosystem to present confidential information about their ongoing research to an invitation-only audience and receive real-time feedback from other experts in the field.

Gathering the key players in the ALS field a single room creates an atmosphere ripe for collaboration, allowing research to move rapidly from the laboratory to the clinic. With limited treatment options and a predicted large increase in cases, attention has turned to in vitro ALS models that use human iPSCs from healthy or ALS patient donors.

If you’re attending the meeting, David would love to connect and discuss how our well‑characterized iPSC‑derived cells from affected (SOD1, TDP-43, or C9orf72) and unaffected donors, alongside our specialist services, can support your ALS research and therapeutic programs.

Learn more about our ALS offerings: https://hubs.la/Q04cJ5sh0

If you aren't at the meeting, contact us on [email protected] to talk to us about how we can help with your projects.

Address

Cambridge
CB101XL

Telephone

+44(0)1223 751 051

Website

Alerts

Be the first to know and let us send you an email when Axol Bioscience Ltd. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Axol Bioscience Ltd.:

Shortcuts

Featured

Share

Category